Nové možnosti léčby nemalobuněčného karcinomu plic
| Title in English | New possibilities in the treatment of non-small cell lung cancer |
|---|---|
| Authors | |
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Pneumology |
| Keywords | non-small cell lung cancer; targeted treatment; gefitinib; afatinib; crizotinib |
| Description | Lung cancer is a disease associated with hiqh mortality. Seeking to improve the poor prognosis and unsatisfactory results obtained so far in patients with metastatic and locoregionally advanced non-small cell lung cancer (NSCLC) other new drugs undergo development and clinical testing (vandetanib, nintedanib, crizotinib). Clinical trials help to determine the correct position of substances in the therapy of NSCLC that have already been introduced (pemetrexed, gefitinib, erlotinib, bevacizumab), and drugs used in other tumour types have also been tested (cetuximab, trastuzumab, pertuzumab). Important components of new approaches to the therapy of lung cancer are recent advances in immunotherapy and vaccination for NSCLC. |